Health
Platform to predict future AF/atrial flutter nets breakthrough device designation – Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter,…
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected] to Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter, developed in collaboration with Geisinger.
The platform (Tempus ECG Analysis Platform, Tempus and Geisinger) is designated for use in patients aged 40 years and older who do not…
-
General10 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News19 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News10 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News9 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years